Skip to main content

Table 2 Description of empiric therapy *.

From: Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae

FACTOR CASE FATALITY WITH FACTOR CASE FATALITY WITHOUT FACTOR RELATIVE RISK (95% CI) P-VALUE
Empiric by t = 0 7/29 (24%) 9/50 (18%) 1.34 (0.56-3.22) NS
Empiric by t = 8 hours 12/48 (25%) 4/31 (13%) 1.94 (0.69-5.47) NS
Empiric by t = 24 hours 14/68 (21%) 2/11 (18%) 1.13 (0.30-4.32) NS
Empiric by t = 48 hours 15/74 (20%) 1/5 (20%) 1.01 (0.17-6.20) NS
Empiric at t > 48 hours 0/3 (0%) 16/76 (21%) 0.00 NS
Never received empiric therapy. 0/1 (0%) 16/78 (21%) ... ...
Empiric Treatment Class     
Carbapenem 0/10 (0%) 16/69 (24%) 0.00 () 0.09
Aminoglycoside 1/7 (14%) 15/72 (21%) 0.67 (0.10-4.41) NS
Fluoroquinolone 3/13 (23%) 13/66 (20%) 1.17 (0.39-3.54) NS
Beta-lactam/Beta-lactamase inhibitor combination 6/16 (38%) 10/63 (16%) 2.36 (1.01-5.53) 0.06
Cephalosporin 5/30 (17%) 11/49 (22%) 0.74 (0.29-1.93) NS
Beta-lactam 0/5 (0%) 16/74 (22%) 0.00 () NS
  1. * Empiric therapy was defined as that therapy initiated prior to the availability of blood culture results and sensitivities.
\